Skip to main content
Glama

Coingecko

by io.github.pipeworx-io

Resolve Entity

resolve_entity
Read-onlyIdempotent

"What's the ticker for…" / "find the CIK for…" / "what's the LEI for…" / "what's the RxCUI for…" / "look up the ID for…" / "what is X's official identifier" / "who owns X" / "is X a subsidiary of Y" — resolve a user-spoken NAME to the canonical/official identifiers other tools require as input. Use FIRST whenever you have a name but need an ID. SUPPORTED TYPES: "company" (cross-source identity spine: 10-digit CIK + ticker + company_name from SEC EDGAR, legal-entity LEI from GLEIF with parent/ultimate-parent/children ownership when the LEI resolves, and security FIGI from OpenFIGI — by exact ticker map when a ticker is implied, and otherwise by name search, so NON-EQUITY instruments that never have a ticker (municipal and corporate bonds, notes, authority debt) DO resolve here; when a name matches more than one instrument it asserts nothing and returns figi_candidates to pick from, which is the correct answer to an issuer name that does not identify a single bond; every identifier is labelled with the source that established it, and an identifier that could NOT be resolved is stated explicitly under unresolved rather than omitted — accepts ticker, CIK, ISIN, or company name as input; an ISIN like "CH0038863350" resolves to the LEGAL ENTITY that issued the security via the GLEIF ISIN-to-LEI mapping, covering non-US issuers EDGAR cannot reach), "drug" (returns RxCUI + ingredient + brand from RxNorm + pipeworx://rxnorm/concept/{rxcui} citation; accepts brand or generic name). LEI/FIGI enrichment degrades gracefully — if GLEIF or OpenFIGI is unavailable, the EDGAR identifiers still return. Each call cascades through several lookup endpoints internally — using resolve_entity replaces 2-3 manual lookups.

Input Schema

TableJSON Schema
NameRequiredDescriptionDefault
typeYesEntity type: "company" or "drug".
valueYesFor company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., "ozempic", "metformin"). Pass the ENTITY NAME ONLY — for a bond that is the ISSUER exactly as printed ("NEW YORK ST DORM AUTH"), never the question's full noun phrase ("NEW YORK ST DORM AUTH revenue bonds"): the FIGI lookup matches instrument names, so trailing security-class words match nothing.

Schema Changelog

Changes observed during successful MCP inspections. Dates show when Glama detected each change.

  1. Changed1 schema field changed
    • changedInput schema / properties / value / description
      Previous value: -"For company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., \"ozempic\", \"metformin\")."New value: +"For company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., \"ozempic\", \"metformin\"). Pass the ENTITY NAME ONLY — for a bond that is the ISSUER exactly as printed (\"NEW YORK ST DORM AUTH\"), never the question's full noun phrase (\"NEW YORK ST DORM AUTH revenue bonds\"): the FIGI lookup matches instrument names, so trailing security-class words match nothing."
  2. First observed

TDQS

A4.5/5.0
Behavior5/5

Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

Beyond the readOnly and idempotent annotations, the description discloses important runtime behavior: unresolved identifiers are explicitly listed under 'unresolved', ambiguous security matches return 'figi_candidates', and LEI/FIGI enrichment degrades gracefully when upstream sources are unavailable. This adds substantial behavioral context the annotations do not provide.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Conciseness3/5

Is the description appropriately sized, front-loaded, and free of redundancy?

The description is front-loaded with user-phrase examples and a clear usage directive, but it is a very long, dense run-on passage with heavy parenthetical asides. The content is valuable, but the structure makes it harder for an agent to parse quickly than a more sectioned or smaller description would be.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Completeness5/5

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

For a tool with no output schema and high complexity, the description is remarkably complete: it covers accepted inputs, resolved identifiers, ownership data, ambiguity handling, unresolved fields, provenance labels, and fallback behavior. An agent has enough context to call the tool and interpret its results correctly.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Parameters4/5

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

The schema already documents both parameters thoroughly, but the description adds meaning beyond it by mentioning ISIN as an accepted input, explaining ticker-implied mapping for FIGI, and clarifying that the value must be the entity name only rather than the full query phrase. This is useful supplementary guidance, though the schema itself already carries much of the burden.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Purpose5/5

Does the description clearly state what the tool does and how it differs from similar tools?

The description names a specific action — resolving a user-spoken name to canonical/official identifiers — and supports it with concrete examples ('ticker for…', 'CIK for…', 'LEI for…'). It also enumerates supported entity types and what each resolves to, making the tool's scope unmistakable and distinct from sibling tools that operate on already-resolved entities.

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Usage Guidelines4/5

Does the description explain when to use this tool, when not to, or what alternatives exist?

The description gives an explicit trigger condition: 'Use FIRST whenever you have a name but need an ID.' It also clarifies edge cases (non-equity instruments, ISINs, ambiguous matches). It does not name specific sibling tools to use instead, but the context is clear enough for an agent to select this tool.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.

All Coingecko toolsInspect
Try in Browser
RayrunBuild, deploy, and operate MCP servers without becoming an infrastructure team.ray.runAd

Glama MCP Gateway

Add one secure layer between your agents and this server.

TDQS

A3.6/5.0
Disambiguation2/5

Several tools are near-duplicates or have heavily overlapping responsibilities (ask_pipeworx / ask_pipeworx_beta / ask_pipeworx_grounded, polymarket_arbitrage / polymarket_edges / polymarket_fill_risk, and ai_visibility_check / scan_competitor_ai_presence). The many meta/entry-point tools (discover_tools, suggest_questions, pipeworx_trending) also blur the boundary between discovery and execution.

Naming Consistency2/5

Tool names mix imperative verb-first patterns (get_coin, search_coins, validate_claim) with noun-phrase labels (bet_research, entity_profile, pipeworx_trending, polymarket_edge_tracker) and inconsistent prefixes. Snake_case is consistent, but the naming grammar and verb styles are not.

Tool Count2/5

35 tools is well past the comfortable range, and the count feels inflated by duplicate routing modes, overlapping polymarket scanners, and generic memory/meta utilities. A server nominally named Coingecko carries only 4 crypto tools while the overwhelming majority belong to unrelated domains.

Completeness2/5

As a CoinGecko server, the surface is severely incomplete: search/get/market/trending exist but historical prices, OHLC, exchanges, categories, and coin details are missing. As a broader data/prediction-market utility it is more expansive, but the lack of a coherent domain makes coverage impossible to assess as a single product.

Resources